A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
Public ClinicalTrials.gov record NCT01781572. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma
Study identification
- NCT ID
- NCT01781572
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 102 participants
Conditions and interventions
Interventions
- LEE011 Drug
- MEK162 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2013
- Primary completion
- Jan 14, 2018
- Completion
- Feb 19, 2018
- Last update posted
- Dec 6, 2020
2013 – 2018
United States locations
- U.S. sites
- 7
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Dept of Oncology | San Francisco | California | 94101 | — |
| California Pacific Medical Center Onc Dept | San Francisco | California | 94120-7999 | — |
| Karmanos Cancer Institute Dept of Oncology | Detroit | Michigan | 48201 | — |
| Memorial Sloan Kettering Cancer Center Dept Oncology | New York | New York | 10021 | — |
| Columbia University Medical Center- New York Presbyterian Onc Dept. | New York | New York | 10032 | — |
| Vanderbilt University Medical Center SC - Dept of Oncology . | Nashville | Tennessee | 37232 | — |
| University of Texas/MD Anderson Cancer Center Dept of Onc. | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01781572, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 6, 2020 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01781572 live on ClinicalTrials.gov.